NeuroOne Medical Technologies Corporation has announced the appointment of David Wambeke as Chief Business Officer, accompanied by his personal purchase of 1,000,000 shares of company common stock. The medical technology company, which focuses on transforming surgical diagnosis and treatment of neurological disorders, gains an executive with extensive healthcare leadership and capital markets experience during a period of strategic expansion.
Wambeke will lead NeuroOne's drug delivery program and collaborate with the executive team to advance clinical development and commercialization strategy. His responsibilities include refining product requirements for preclinical and clinical-stage devices, expanding relationships with key opinion leaders in targeted disease areas, and engaging prospective pharmaceutical partners to maximize the strategic value of the Company's emerging drug delivery platform. He will also oversee investor relations, strengthening market communication and broadening engagement with the investment community, while supporting strategic business development initiatives including partnerships and corporate transactions.
"David brings a rare combination of public company experience, capital markets expertise, and a demonstrated ability to translate strategic vision into operational and clinical execution," said Dave Rosa, CEO of NeuroOne. The company believes Wambeke will be instrumental in sharpening messaging, deepening investor engagement, and advancing business development activities that support long-term value creation.
Wambeke most recently served as Chief Business Officer at DiaMedica Therapeutics, where he led the strategic expansion of the company's lead biologic into preeclampsia, establishing and overseeing a first-in-pregnancy Phase 2 clinical trial that delivered positive results and contributed to substantial shareholder value creation. Prior to DiaMedica, he spent approximately 16 years at Craig-Hallum Capital Group in life sciences investment banking, advising public and private healthcare companies on equity financings, mergers and acquisitions, and strategic transactions.
"I'm excited to join NeuroOne at such a pivotal moment and to meaningfully align myself with shareholders through my investment," said Wambeke. He noted that with four FDA 510(k)-cleared devices and a strategic partnership with Zimmer Biomet, NeuroOne has validated its platform technology and established a strong commercial foundation in epilepsy and trigeminal nerve applications. As the Company continues to scale commercialization across these cleared indications, Wambeke believes even greater opportunities lie ahead in basivertebral ablation, drug delivery, and spinal cord stimulation.
In conjunction with his appointment, Wambeke purchased 1,000,000 shares of NeuroOne's common stock at a purchase price of $0.6704 per share, representing the closing price of the Company's common stock on February 27, 2026. NeuroOne intends to use the net proceeds from this sale to support ongoing clinical and product development activities, as well as for working capital and general corporate purposes. The shares sold to Wambeke have not been registered under the U.S. Securities Act of 1933, as amended, or any state or other applicable jurisdiction's securities laws, and may not be offered or sold in the United States absent such registration or an applicable exemption.
In connection with Wambeke's appointment, the Company granted him an inducement stock option to purchase 500,000 shares of common stock of NeuroOne pursuant to the NeuroOne Medical Technologies Corporation 2021 Inducement Plan. The inducement grant was approved by the Company's compensation committee of the board of directors and was effective as of Wambeke's first date of employment, March 1, 2026, and was a material inducement to his acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $0.6704 per share, which is equal to the closing price of NeuroOne's common stock on the grant date, and a 10-year term.
NeuroOne Medical Technologies Corporation markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering combination diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery and spinal cord stimulation programs. For more information, visit https://nmtc1.com.
